ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

CTLA4

cytotoxic T-lymphocyte associated protein 4 · also CD152, CD, GSE, CTLA-4 · CD molecules

15 programs in company-led studies act on CTLA4, from 14 companies: 8 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (13 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
cadonilimabruleAkeso–phase 34522 runningPDCD1NCIt
tremelimumabruleAstraZeneca–phase 34718 running–NCIt
volrustomigAstraZeneca–phase 31917 runningPDCD1a judged reading
Anti-CTLA-4 Monoclonal Antibody SHR-8068ruleJiangsu HengRui Medicine–phase 31615 running–NCIt
Iparomlimab/TuvonralimabruleQilu Pharmaceutical–phase 32214 runningPDCD1NCIt
gotistobartruleOncoC4–phase 355 running–NCIt
erfonrilimabruleAlphamab Oncology–phase 3142 runningCD274NCIt
Anti-CTLA-4 Monoclonal Antibody IBI310ruleInnovent Biologics–phase 3112 running–NCIt
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010ruleHC Biopharma–phase 222 runningPDCD1, VEGFANCIt
GB268ruleEddingpharm (Zhuhai)–phase 222 running–the studies' text
LM-168Sino Biopharmaceutical–phase 222 running–the company's pipeline
zalifrelimabruleAgenus–phase 261 running–NCIt
porustobartruleHarbour BioMed (Guangzhou)–phase 251 running–NCIt
lorigerlimabruleMacroGenics–phase 241 runningPDCD1NCIt
CS2009ruleCStone Pharmaceuticals–phase 211 runningVEGFAthe studies' text

Also acted on by the same programs

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.